Clinical trial

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-07-01

PhasePHASE4

Study timeline

Study start (unknown)2005-07-01Date precision: month

Registry last updated2010-05-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV-Associated Lipodystrophy Syndromeunresolved

Interventions

Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)DRUG

continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)DRUG

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

HoustonTexas, United States1 TorontoOntario, Canada1 MadridSpain1 BarcelonaSpain1 ParisFrance1 MilanItaly1 ValenciaSpain1 LyonFrance1 OttawaOntario, Canada1 RomaItaly1 Fort LauderdaleFlorida, United States1 MálagaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00135356 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.